As announced via Business Wire, BEACON-Neuro.AI Inc., a Washington University in St. Louis startup, and Innolitics, a medical-device software and FDA regulatory services provider, have advanced an artificial intelligence prototype into the federal regulatory pipeline. The joint project centers on BEACONPredict, an algorithm that calculates the risk of malignant cerebral edema following an acute ischemic stroke.
Malignant cerebral edema represents a severe complication in neurocritical care. The software analyzes early changes in brain imaging alongside specific clinical variables to generate a risk estimate. This data allows medical teams to determine if a patient requires increased monitoring or decompressive surgery before their condition deteriorates. The system functions as a clinical decision support tool and is not yet cleared or approved for commercial distribution.
"BEACON-Neuro.AI brought new science to address a clinical need nobody was serving well. Our job was to give it a route the FDA would accept, and the designation came through on the first cycle. That happens when the clinical team and the regulatory team are working off one plan instead of passing documents back and forth," said Yujan Shrestha, MD, Partner, Innolitics.
The underlying clinical science originated in a neurocritical-care laboratory at WashU Medicine.
"We built the science at WashU Medicine, but taking it to patients means clearing the FDA, and that is not what a research lab is set up to do. Partnering with Innolitics, BEACON-Neuro.AI took BEACONPredict from lab code to an FDA Breakthrough Device in a single submission cycle, and we are building the product together now," said Raj Dhar, MD, Co-Founder of BEACON-Neuro.AI and Professor of Neurology, WashU Medicine.
The product received its Breakthrough Device Designation, a premarket program rather than a marketing authorization, during its initial review cycle and is pursuing market clearance through the De Novo pathway. The software has also entered the FDA's TAP pilot program, which offers direct regulatory engagement and a potential route to an accelerated CMS NTAP reimbursement pathway. To finance the remaining clearance process and commercial launch, the startup is raising a $0.5 million pre-seed round, which will precede a planned $2.7 million seed round.
